Kalaris Therapeutics Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Find out what a historical investment in Kalaris Therapeutics Inc would be worth today using our KLRS stock calculator.
$165.89M
-
0.00%
187.24K
$8.87
$7.82
$8.45
$12.90
$2.14
Ready to start your investing journey with Stake?
Open an accountKLRS FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in KLRS
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in KLRS
on Stake
Buy KLRS from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of KLRS from only US$10 with fractional shares
